Docetaxel News and Research

RSS
Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

Value of PD-L1 testing in NSCLC debated

Value of PD-L1 testing in NSCLC debated

Experimental drug improves survival rate of majority of lung cancer patients compared to standard chemotherapy

Experimental drug improves survival rate of majority of lung cancer patients compared to standard chemotherapy

Multi-gene test can help identify early breast cancer patients who can safely be spared chemotherapy

Multi-gene test can help identify early breast cancer patients who can safely be spared chemotherapy

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

ASTRO's new research journal 'Advances in Radiation Oncology' closes first issue

ASTRO's new research journal 'Advances in Radiation Oncology' closes first issue

NICE recommends Xofigo (radium-223 dichloride) for prostate cancer patients after treatment with docetaxel

NICE recommends Xofigo (radium-223 dichloride) for prostate cancer patients after treatment with docetaxel

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

FDA approves non-alcoholic Docetaxel Injection

FDA approves non-alcoholic Docetaxel Injection

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

Immunotherapy more effective than chemotherapy in treating patients with advanced lung cancer

Immunotherapy more effective than chemotherapy in treating patients with advanced lung cancer

Study offers new view of how cancer cells transform normal cells through 'metastatic hijacking'

Study offers new view of how cancer cells transform normal cells through 'metastatic hijacking'

NICE recommends Xofigo (radium-223 dichloride) for patients with advanced prostate cancer

NICE recommends Xofigo (radium-223 dichloride) for patients with advanced prostate cancer

Prostate cancer market to expand at CAGR of 9.5% to $13.6 billion by 2021

Prostate cancer market to expand at CAGR of 9.5% to $13.6 billion by 2021

Entry of eleven novel therapies expected to drive NSCLC market's growth to $12.7 billion in 2024

Entry of eleven novel therapies expected to drive NSCLC market's growth to $12.7 billion in 2024

Nivolumab vs docetaxel updated results for nonsquamous, squamous NSCLC

Nivolumab vs docetaxel updated results for nonsquamous, squamous NSCLC

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC